With a market cap of $113.7 billion, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines for oncology, hematology, immunology, cardiovascular, and neuroscience diseases. It serves patients worldwide with leading therapies such as Eliquis, Opdivo, Revlimid, Orencia, and Yervoy.
BMY is set to unveil its fiscal Q4 2025 results before the market opens on Thursday, Feb. 5. Ahead of this event, analysts expect the Princeton, New Jersey-based company to report an adjusted EPS of $1.65, down 1.2% from $1.67 in the year-ago quarter. However, it has surpassed Wall Street's bottom-line estimates in the past four quarters.
For fiscal 2025, analysts project the biopharmaceutical giant to report adjusted EPS of $6.53, a surge of 467.8% from $1.15 in fiscal 2024.
BMY stock has declined 1.7% over the past 52 weeks, lagging behind the S&P 500 Index's ($SPX) 17.7% gain and the State Street Health Care Select Sector SPDR ETF's (XLV) 12% rise over the same period.
Shares of Bristol Myers Squibb climbed 7.1% on Oct. 30 after the company reported stronger-than-expected Q3 2025 adjusted EPS of $1.63 and revenue rising 3% to $12.2 billion. Investor sentiment was further boosted by 18% Growth Portfolio revenue growth to $6.9 billion, driven by strong performance from its immuno-oncology portfolio, Reblozyl, Camzyos, and Breyanzi. The company also raised its full-year 2025 revenue guidance to $47.5 billion - $48 billion and updated adjusted EPS guidance to $6.40 - $6.60.
Analysts' consensus rating on BMY stock is moderately optimistic, with a "Moderate Buy" rating overall. Out of 29 analysts covering the stock, opinions include nine "Strong Buys,” one "Moderate Buy," 18 "Holds," and one "Strong Sell.” As of writing, it is trading above the average analyst price target of $56.17.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
- These Are the 3 Best Dividend Stocks to Buy for 2026
- Nvidia’s Jensen Huang Warns ‘China Has Twice the Amount of Energy We Have,’ but Trump’s Pro-Energy Plan is the ‘Greatest Thing’ for America
- Gold Rallies, VIX Spikes as Fed Chair Powell Responds to Criminal Indictment
- UnitedHealth Faces Renewed Scrutiny into Its Nursing Home Practices. What Does That Mean for UNH Stock?
